Medicamen Biotech Ltd

Medicamen Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite ongoing challenges in the Pharmaceuticals & Biotechnology sector. The company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside other key financial metrics, reveal a complex picture of valuation attractiveness contrasted with operational and market headwinds.

Medicamen Biotech Ltd’s shares declined to a fresh 52-week low of Rs.275.95 on 12 Mar 2026, marking a significant downturn amid broader market weakness and company-specific performance concerns. The stock has underperformed its sector and key benchmarks, reflecting ongoing pressures in the Pharmaceuticals & Biotechnology space.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 February 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the company’s current position as of 10 March 2026, providing investors with the latest comprehensive view of the stock’s performance and prospects.

Medicamen Biotech Ltd’s share price declined sharply to a new 52-week low of Rs.277.05 today, marking a significant downturn amid broader market fluctuations. The stock opened with an 8% gap down and has now fallen for two consecutive sessions, underperforming its sector and the broader market indices.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Medicamen Biotech Ltd’s shares declined sharply to a new 52-week low of Rs.292.05 on 25 Feb 2026, marking a significant drop amid broader market gains. The stock underperformed its sector and key benchmarks, reflecting ongoing concerns about its financial performance and valuation metrics.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Medicamen Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, raises questions about the stock's price attractiveness relative to its historical averages and peer group. Despite a recent uptick in share price, the company’s fundamental scores and returns suggest a cautious approach for investors.

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Medicamen Biotech Ltd has experienced a nuanced shift in its technical momentum, with several key indicators signalling a transition from bearish to mildly bearish territory. Despite a recent uptick in price, the stock continues to face headwinds amid mixed signals from MACD, RSI, moving averages, and other technical tools, reflecting a complex outlook for investors in the Pharmaceuticals & Biotechnology sector.

Medicamen Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a nuanced shift in its technical momentum. While some indicators suggest mild bullishness, others point towards a cautious, mildly bearish trend, reflecting a complex market sentiment as the stock trades at ₹400.00, up 1.19% on 9 Jan 2026.

Medicamen Biotech Ltd has experienced a notable shift in price momentum, reflected in a 9.09% gain on 8 Jan 2026, signalling a potential technical turnaround. However, the stock’s broader technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages and other momentum oscillators, suggesting cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and ongoing challenges in the company’s long-term growth trajectory.

Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and valuation considerations that investors should carefully analyse.